United Therapeutics submits FDA NDA for PAH drug ralinepag

Reuters2026/08/28 11:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

United Therapeutics submitted an FDA New Drug Application in June 2026 for ralinepag to treat pulmonary arterial hypertension.
An FDA supplemental New Drug Application was also filed for nebulized treprostinil to treat idiopathic pulmonary fibrosis.
Ralinepag remains investigational. Nebulized treprostinil remains investigational for idiopathic pulmonary fibrosis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via Business Wire (Ref. ID: 20260828683707) on August 28, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

United Therapeutics submits FDA NDA for PAH drug ralinepag

You may also like

Crypto prices